Drugs that contain Cladribine
1. Mavenclad patents expiration
MAVENCLAD's oppositions filed in EPO
MAVENCLAD Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7888328 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(14 days ago) | |
| US8785415 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(14 days ago) | |
| US8377903 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
May, 2026
(2 years from now) | |
| US7713947 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
Oct, 2026
(2 years from now) | |
| US10849919 | EMD SERONO INC | Cladribine regimen for treating progressive forms of multiple sclerosis |
Nov, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 29, 2022 |
Market Authorisation Date: 29 March, 2019
Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusi...
Dosage: TABLET;ORAL
How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage
MAVENCLAD family patents
